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Abstract
Background: Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are characterized by rapid
deterioration and a fatal outcome. Objectives: Admission triggers, treatment efficacy, and care patterns. Methods:
Retrospective analysis of patients with PSP/CBD admitted to an inpatient specialized palliative care service. Results: In 38
patients, there were 63 admissions for swallowing difficulties, falls, pain, impaired communication, cognitive/mood
disturbances, respiratory symptoms, and infection. Mean length of stay was 11.6 days. Treatment response was variable. In
68%, of admission episodes there was stabilization or improvement, 75% were discharged home. In case of readmission, the
mean interval has been 9.7 months. Time since diagnosis and admission triggers were not associated with outcome or death.
Conclusion: Patients showed high symptom load contrasting with discharge rates and subsequent health care utilization.
Brief multidisciplinary interventions might be helpful to preserve autonomy.
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Introduction
Only recently it has been recognized that patients with Parkin-
son’s disease (PD) and atypical Parkinsonian disorders like
progressive supranuclear palsy (PSP), corticobasal degenera-
tion (CBD), and multiple systems atrophy (MSA) benefit from
specialized palliative care,1 a well-established approach for
patients with other disabling and progressive neurologic condi-
tions such as amyotrophic lateral sclerosis. In the absence of
effective disease-modifying pharmacologic management, the
therapeutic goal is to alleviate symptom burden, to preserve
patient autonomy as long as possible, and to provide high qual-
ity end-of-life (EoL) care.
Atypical Parkinsonian disorders present with PD-like symp-
toms but do not or only transiently respond to dopaminergic
drug regimens. Although there is some reduction in life expec-
tancy in patients with PD,2,3 patients diagnosed with atypical
Parkinsonian disorders face a more rapid disease progression
and a poorer prognosis with a median overall survival of 3 to
6 years after diagnosis.4,5 Patients with PSP present with a gra-
dually worsening coordination of gait, speech, and swallowing,
complicated by pain, respiratory, and neuropsychiatric symp-
toms; median survival after onset of symptoms is 5.8 years,6-9
while early onset dysphagia, cognitive impairment, old age,
and time to disability seem to predict poor survival.10 Patients
with CBD have similar clinical features—nonfluent aphasia,
frontal dementia, limb dystonia, and postural instability11—
and considered a spectrum of diseases rather than a distinct
entity by some authors since investigations often lack neuro-
pathologic confirmation.8 Both conditions share the common
etiology of a pathological misfolding of the tau protein.
As these conditions are rare with an age-adjusted PSP
prevalence of 6.4 per 100 000 (95% confidence interval
2.3-10.6)12 and an unknown prevalence for CBD in Europe,
patients with PSP and CBD are usually seen at highly specialized
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neurology outpatient clinics. However, there is little published
information on health care utilization by these patients as disease
progresses toward its final stage. Usually they die at home or in
general hospitals.13 In most cases, bronchopneumonia, aspira-
tion pneumonia, or falls with severe injuries will precipitate the
dying process. Because reimbursement is sometimes linked to a
life expectancy shorter than the observed 15 to 24 months from
the onset of swallowing difficulties in patients with PSP and
CBD,4 hospice programmes may be reluctant to enroll these
patients. Initiation of palliative and hospice care is frequently
delayed by lacking awareness and structural barriers, while at the
same time health status and autonomy of these patients are dete-
riorating rapidly and family caregivers experience a growing
need for multidisciplinary support.
Therefore, to obtain basic information on this cohort’s utili-
zation of health care resources and the role of inpatient pallia-
tive care services in particular, the authors focused on palliative
care unit (PCU) referrals and retrospectively evaluated admis-
sion triggers, overall efficacy of symptom management, and
the patterns of subsequent care.
Patients and Methods
Patients were regularly seen at the movement disorder out-
patient clinic at the Department of Neurology, Klinikum
Grosshadern, Ludwig-Maximilians University Munich (April
2006-December 2012). If in high demand for inpatient care,
they were admitted by the neurology team in charge (GN or
SL) to the institution’s PCU which was run by an integrated
palliative care/neurology team. In patients residing outside
the Munich area, telephone contacts with the general practi-
tioner, home care nurse, informal carer, or the patient her-
self/himself (if possible) facilitated a thorough preadmission
assessment of the acute problems. The study was approved
by the local institutional review board. Written informed con-
sent was not required since it was a retrospective chart review.
For inclusion in the analysis, a clinical diagnosis of PSP or
CBD had to be made before admission to the PCU. In several
cases, magnetic resonance imaging and nuclear imaging had
been performed since onset of the disease. Diagnosis was fur-
ther confirmed upon admission by clinical examination and
review of imaging data, which was conducted by board-
certified movement disorder experts.
The authors retrospectively collected the following
demographic data of all patients by systematically hand
searching all discharge documents: age, sex, neurologic
diagnosis, time since diagnosis, other conditions, and dis-
tance from the patient’s residence to the PCU. Dates of
admission and discharge, length of stay (LoS), time inter-
vals between admissions, and the date of death in the PCU
(if applicable) were recorded. The symptoms on admission
were prospectively assessed by the standard assessment
tools used in the PCU; however, symptoms were not quan-
tified but recorded in a ‘‘yes/no’’ fashion. From the dis-
charge documents, the following categories of features
triggering admission were derived:
 swallowing difficulties included dysphagia, pseudohy-
persalivation, and frequent aspiration resulting from
progressive bulbar involvement;
 gait instability/falls specifically referred to any impair-
ment of posture and locomotion;
 spasticity/pain was defined as impairment of motility
caused by pathological muscle tonus, possibly associ-
ated with musculoskeletal pain;
 impaired communication referred to any dysarthria or
the need for a communication device;
 cognitive/mood disorders included personality changes,
depression, hallucinations, and cognitive impairment;
 respiratory symptoms were defined as cough and dys-
pnea; and
 infection covered both pneumonias and urinary tract
infections.
Each pharmacological and nonpharmacological interven-
tion, regardless of its specific intention (disease modifying or
symptom oriented), was recorded. Symptom control at dis-
charge was documented, and for each symptom a response rate
was calculated (admission episodes with improvement divided
by all admission episodes with this symptom). In addition, the
overall clinical meaningful outcome of each PCU admission
was documented (general stabilization or improvement as
opposed to deterioration). Finally, the setting of patient care
after PCU discharge was documented as well as the health care
structures involved in the subsequent management (home/
home with nursing support/home with palliative care team +
nursing support/nursing home or rehabilitation facility).
Frequencies of the events were analyzed by descriptive sta-
tistics. To detect possible associations between patient vari-
ables (age, sex, distance from home to PCU, time since
diagnosis, time interval between admissions, LoS, or presence
of any of the symptoms) and outcome variables (stabilization/
improvement vs deterioration and death during admission), the
chi-square (w2) test (for dichotomous variables), and the Mann-
Whitney U and Kruskal-Wallis tests (for continuous variables)
were performed. To correct for multiple testing, the Bonferroni
correction was applied when appropriate. Statistical signifi-
cance was assumed at a P value of <.05. IBM SPSS version
20 was used for calculations.
Results
From April 2006 to December 2012, among a total of 649 PCU
admissions, 38 (5.9%) patients with PSP or CBD were identi-
fied: 35 of these patients were clinically diagnosed with PSP
and 3 with CBD.
Table 1 displays the demographic characteristics of this
cohort. In short, patients were predominantly elderly individu-
als, all of a caucasian origin, and the female:male ratio was
balanced. They had a cardiovascular comorbidity profile typi-
cally seen in this age-group (data not shown) and had long-
standing PSP or CBD (mean time from first diagnosis to PCU
admission: 4.5 years). The LoS value of ‘‘0 days’’ in 1 patient
478 American Journal of Hospice & Palliative Medicine® 33(5)
resulted from death on the day of admission. Eighteen patients
were admitted more than once to the PCU after a median time
interval of 9.7 months; in total, there were 63 admissions in
these 38 patients. All study participants were living at home
or in a nursing facility at the time of PCU admission and were
recruited from a large catchment area covering the whole of
Germany.
Figure 1 shows the symptoms most frequently triggering
admission to the PCU and the numbers of responses to treat-
ment. Response to treatment ranged from 4 (11%) of the 37
patients who benefitted from approaches addressing swallow-
ing difficulties up to 15 (52%) of the 29 who had an improve-
ment in their spasticity and pain.
Presence of communication deficits was associated with gait
instability/falls (w2 test, P ¼ .018 after Bonferroni correction
for multiple testing). Patients who presented with swallowing
problems were less likely to have cognitive/mood disturbances
(P ¼ .018). However, no further symptom clustering could be
observed. General stabilization or improvement was observed
in 43 (68%) of the 63 admission episodes, deterioration or death
in 15 (24%) of the 63, and for 5 (8%) of the 63 admission episodes
outcome data were missing (Figure 2A). Symptoms triggering
admission did not correlate with overall outcome or death during
admission (w2 test, P > .05) after the Bonferroni correction; a trend
toward stable or improved outcome in patients presenting with
swallowing difficulties did not reach statistical significance
(P ¼ .056). Age, distance of residence to the PCU, time since
diagnosis, LoS, and time intervals between admissions did not
correlate with either overall outcome or death in the PCU
(Mann-Whitney U test, P > .05) nor did sex (w2 test, P > .05). Place
of subsequent care (Figure 2B) was not associated with presenting
symptoms, sex (w2 test, P > .05), and the other patient variables
(Kruskal-Wallis test, P > .05).
Table 2 specifies the most common therapeutic interven-
tions (pharmacological and nonpharmacological) actually per-
formed. In addition, physiotherapy, swallowing exercises,
rehabilitation, nutritional counselling, and psychological
support were provided to all patients if needed. The aim of any
of these actions was palliation of symptoms and maintenance
of patient autonomy.
Figure 2B shows the distribution of settings of care after dis-
charge from the PCU. In 75% of admission episodes, patients
were discharged home—without professional caregiver sup-
port at home (47%), with nursing support only (9%), or with
a hospice or palliative care team + nursing support (19%).
Two discharges were made to a nursing home, one to a rehabi-
litation facility.
Discussion
In this retrospective patient chart-based survey on 63 PCU
admissions in a cohort of 38 patients with PSP or CBD, the
authors observed that (1) these patients had long-standing dis-
ease with a median time from diagnosis of 4 years and experi-
enced death in the PCU in only 14% of cases, (2) they were
referred across long distances of up to 775 km for highly spe-
cialized symptom management, indicating that symptom bur-
den might not be well controlled by local support, (3) they
presented with a variety of symptoms such as swallowing dif-
ficulties that were only partly amenable to interventions, with
treatment responses ranging from 11% (swallowing difficul-
ties) to 52% (spasticity and pain), (4) some of the agents used
here may be unfamiliar to palliative care physicians (eg, anti-
Parkinson drugs and botulinum toxin), (5) symptoms refractory
to therapy were not associated with an adverse outcome at the
time of discharge, (6) in 68% of admission episodes, there was
stabilization or improvement in symptoms, and (7) in 75%,
patients returned home after a brief inpatient period, the major-
ity without specialist support, with an interval of several
months between readmissions. Surprisingly, high symptom
load seemed to contrast with low health care utilization after
discharge.
It has been acknowledged by the UK National Health Ser-
vice that ‘‘palliative care requirements of people with PD should
be considered throughout all phases of the disease.’’ (p. 24)14
This applies also to patients with atypical Parkinsonian disor-
ders. They experience early disability15 but are usually diag-
nosed late in the course of their disease,16 commonly present
with symptoms such as dysarthria or dysphagia, which are asso-
ciated with a survival of only 15 to 24 months,17 suffer fre-
quently from depression, which affects their subjective health
status,18 and have a higher risk of respiratory-related death
than patients with PD.13 A longitudinal UK study of 50 PD,
15 PSP, and 17 MSA patients having clinical characteristics
similar to our cohort recently found a complex mix of poorly
controlled symptoms, a high rate of deterioration at 1 year, and
prediction of future symptoms by palliative problems.19
According to a recent questionnaire survey involving 69
patients with PSP in Germany,16 despite significant disabilities
87% of them were living at home with little or no support from
professional caregivers, which is in line with the findings of
this work. However, a Swedish study of 23 patients with PSP,
CBD, or MSA revealed a high need for care by different
Table 1. Patient Characteristics
Age, mean + SD (range), years 68.6 + 7.2 (51-86)
Sex: females/males, no. 18/20
Diagnosis: PSP/CBD, no. 35/3
Distance pt.’s home—PCU, mean +
SD (range), km
114 + 173.2 (3-775)
LoS in the PCU, mean + SD (range),
days
11.6 + 5.9 (0-34)
Patients with 1 admission, no. 20 (53%)
Patients with 2 admissions, no. 11 (29%)
Patients with 3 or more admissions, no. 7 (18%)
Time since diagnosis, mean + SD
(range), years
4.5 + 2.9 (0.75-12)
Interval between readmissions, mean +
SD (range), months
9.7 + 10.6 (0.25-40)
Abbreviations: CBD, corticobasal degeneration; LoS, length of stay; PCU,
palliative care unit; PSP, progressive supranuclear palsy; SD, standard
deviation.
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specialties including palliative care because of complex,
disease-related symptom burden.20 In the present study,
although long time intervals suggested a chronic rather than a
progressing, fatal condition, the symptoms that led to admis-
sion were incapacitating and required management at a facility
with special expertise in both neurodegenerative diseases and
palliative care. Even with this support, treatment response was
very variable. Despite this narrow margin of benefit, in 68% of
admission episodes, patients experienced stabilization or
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Figure 1. Prevalence of symptoms at admission (black columns) and response (gray columns); * response of infections was not documented.
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Figure 2. A, Outcome of all admission episodes as documented at discharge (no., %) and (B) place of outpatient care and professional home
care after discharge (no., %). PCU indicates palliative care unit.
480 American Journal of Hospice & Palliative Medicine® 33(5)
be discharged home. Thus, the role of the PCU for patients with
PSP and CBD was to provide a multidisciplinary, short-term
intervention with the aim to preserve and possibly restore
long-term function. Only in a minority (14%) of admissions,
EoL care was indicated.
Limitations are of methodological nature. First of all, the
study design was retrospective. Although a prospective evalua-
tion with validated instruments therefore could not be per-
formed, this approach is in accordance with the purpose of
the study to capture triggers for admission and not symptom
severity. Second, correlations must be interpreted cautiously
as absolute numbers were small and cases were not indepen-
dent. Therefore, etiologic conclusions cannot be drawn from
the data. Third, as data collection was cross-sectional by design
and restricted to inpatient admissions only, there is no informa-
tion about disease trajectories and the results do not reflect the
different settings of care.
However, to the authors’ knowledge, this is the first report
on PSP or CBD patients’ symptoms and conditions that trig-
gered admission to a PCU. The main strength of this work
is data collection in a pathophysiologically and clinically
homogenous population. Availability of a highly specialized
movement disorder service enabled the authors to recruit
patients from a large catchment area and in any stage of dis-
ease progression. Thus, selection bias was minimized, and
this sample is likely to provide a representative picture of the
whole range of issues relating to advancing PSP or CBD dis-
ease. These data confirm results published by other groups
that mostly enrolled only small PSP or CBD subgroups within
larger study populations.17,19,20
Several unresolved issues arise from the results of this study.
Regarding health care structures, gaps have been identified in
this and other work. Therefore, the question why a high preva-
lence of symptoms goes along with low health care utilization
has to be addressed by prospectively evaluating the role of
professional and informal caregivers. Furthermore, from a drug
researcher’s point of view, hallmarks of PSP and CBD are
absence of empirical evidence, variable treatment responses,
and low disease prevalence. Carefully published case series
(eg, on the response of spasticity/pain to opioids) will be a first
step toward gathering experience in order to optimize symptom
management, confirmed by clinical trials where appropriate.
This work documents specialist palliative care needs in a
German population of patients with PSP and CBD admitted
to a PCU indicating high burden both for the patients and
their caregivers. The key challenge is to translate these find-
ings of PCU utilization by patients with a rare condition and
highly specialized needs into a clinical model of care for
these and similar patient cohorts. Medical associations such
as the European Society of Cardiology21 and the American
Society of Clinical Oncology22 advocate integration of pal-
liative care into their respective field by different approaches.
However, both specialist neurology services and the 2-level
generalist/specialty palliative care model proposed recently23
may fail to provide adequate support to patients with PSP
and CBD: fine-tuning of specific drug regimens alongside
resource-consuming palliative interventions may be required
while integrated neurology/palliative collaboration is not
routinely established. ‘‘Third-level,’’ multidisciplinary pal-
liative care at selected centers may help to bridge this gap,
to promote continuity of care, and to preserve long-term
function and autonomy.
Acknowledgments
The authors are indebted to Piret Paal and Alexander Crispin for
giving helpful statistical advice.
Declaration of Conflicting Interests
The authors declared no potential conflicts of interest with respect to
the research, authorship, and/or publication of this article.
Funding
The authors received no financial support for the research, authorship,
and/or publication of this article.
References
1. Wilcox SK. Extending palliative care to patients with Parkinson’s
disease. Br J Hosp Med (Lond). 2010;71(1):26-30.
Table 2. Summary of therapeutic interventions
Treatment option Specification n % of admissions (n¼ 63)
Anti-Parkinson drugs L-Dopa, amantadine, rotigotin, bornaprin, rasagiline 27 43
Antidepressants, neuroleptics, and
anticholinergics
Amitriptylin, mirtazapine, quetiapin, melperon,
butylscopolamin
20 32
Opioids Morphine, tilidin, tramadol, tapentadol 16 25
Treatment-related discussions EoL discussion, decisions on artificial nutrition and hydration 15 24
Antibiotics Broad-spectrum penicillins, chinolones, macrolides 15 24
Nonsteroidal anti-inflammatory drugs Metamizol, diclofenac 12 19
Spasmolytic analgesics Flupirtin maleate, baclofen 11 17
Benzodiazepines Midazolam, lorazepam 10 16
Botulinum toxin Local injection therapy 7 11
Invasive procedures Urinary catheter, PEG insertion 6 10
Palliative sedation Continuous midazolam or propofol infusion 2 3
Abbreviations: EoL, end of life; PEG, percutaneous endoscopic gastrostomy.
Bükki et al 481
2. Fall PA, Saleh A, Fredrickson M, Olsson JE, Granerus AK.
Survival time, mortality, and cause of death in elderly patients
with Parkinson’s disease: a 9-year follow-up. Mov Disord.
2003;18(11):1312-1316.
3. Hawkes CH. Parkinson’s disease and aging: same or different
process? Mov Disord. 2008;23(1):47-53.
4. Litvan I, Mangone CA, McKee A, et al. Natural history of
progressive supranuclear palsy (Steele-Richardson-Olszewski
syndrome) and clinical predictors of survival: a clinicopatho-
logical study. J Neurol Neurosurg Psychiatry. 1996;60(6):
615-620.
5. Wenning GK, Litvan I, Jankovic J, et al. Natural history and sur-
vival of 14 patients with corticobasal degeneration confirmed at
postmortem examination. J Neurol Neurosurg Psychiatry. 1998;
64(2):184-189.
6. Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh
PN. Riluzole treatment, survival and diagnostic criteria in Parkin-
son plus disorders: the NNIPPS study. Brain. 2009;132(pt 1):
156-171.
7. Golbe LI, Ohman-Strickland PA. A clinical rating scale for
progressive supranuclear palsy. Brain. 2007;130(pt 6):1552-1565.
8. Ludolph AC, Kassubek J, Landwehrmeyer BG, et al. Tauopathies
with parkinsonism: clinical spectrum, neuropathologic basis, bio-
logical markers, and treatment options. Eur J Neurol. 2009;16(3):
297-309.
9. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear
palsy. A heterogeneous degeneration involving the brain stem,
basal ganglia and cerebellum with vertical gaze and pseudobulbar
palsy, nuchal dystonia and dementia. Arch Neurol. 1964;10:
333-359.
10. Dell’aquila C, Zoccolella S, Cardinali V, et al. Predictors of sur-
vival in a series of clinically diagnosed progressive supranuclear
palsy patients. Parkinsonism Relat Disord. 2013;19(11):980-985.
11. Reich SG, Grill SE. Corticobasal degeneration. Curr Treat
Options Neurol. 2009;11(3):179-185.
12. Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive
supranuclear palsy and multiple system atrophy: a cross-
sectional study. Lancet. 1999;354(9192):1771-1775.
13. Papapetropoulos S, Singer C, McCorquodale D, Gonzalez J, Mash
DC. Cause, seasonality of death and co-morbidities in progressive
supranuclear palsy (PSP). Parkinsonism Relat Disord. 2005;
11(7):459-463.
14. National Health Service Evidence, Clinical knowledge summa-
ries, Parkinson’s disease—national clinical guideline for diagno-
sis and management in primary and secondary care. Web site:
www.nice.org.uk/CG035. Published May 28, 2006. last accessed
December 16, 2014; anticipated update October 2016.
15. Duff K, Gerstenecker A, Litvan I. Functional impairment in pro-
gressive supranuclear palsy. Neurology. 2013;80(4):380-384.
16. Hensler M, Paul S, Abright C, Lorenzl S. Progressive supranuc-
lear palsy: living environment of the patients [in Germany]. Ner-
venarzt. 2011;82(2):207-214.
17. Muller J, Wenning GK, Verny M, et al. Progression of dysarthria
and dysphagia in postmortem-confirmed parkinsonian disorders.
Arch Neurol. 2001;58(2):259-264.
18. Schrag A, Sheikh S, Quinn NP, et al. A comparison of depression,
anxiety, and health status in patients with progressive supranuc-
lear palsy and multiple system atrophy. Mov Disord. 2010;
25(8):1077-1081.
19. Higginson IJ, Gao W, Saleem TZ, et al. Symptoms and quality of
life in late stage Parkinson syndromes: a longitudinal community
study of predictive factors. PLoS One. 2012;7(11):e46327.
20. Sjostrom AC, Holmberg B, Strang P. Parkinson-plus patients—an
unknown group with severe symptoms. J Neurosci Nurs. 2002;
34(6):314-319.
21. Jaarsma T, Beattie JM, Ryder M, et al. Palliative care in heart fail-
ure: a position statement from the palliative care workshop of the
Heart Failure Association of the European Society of Cardiology.
Eur J Heart Fail. 2009;11(5):433-443.
22. Ferris FD, Bruera E, Cherny N, et al. Palliative cancer care a
decade later: accomplishments, the need, next steps—from the
American Society of Clinical Oncology. J Clin Oncol. 2009;
27(18):3052-3058.
23. Quill TE, Abernethy AP. Generalist plus specialist palliative
care—creating a more sustainable model. N Engl J Med. 2013;
368(13):1173-1175.
482 American Journal of Hospice & Palliative Medicine® 33(5)
